ATR

AptarGroup Inc (ATR) | Rumor.io

AptarGroup

ATR

Attention (50-day avg)0%

Attention rank (50-day avg)#2,593

Bullish sentiment (50-day avg)100%

Price to earnings ratio22.5

Market capitalization7.9B

Earnings per share5.54

Dividend yield (TTM)1.41%

Revenue (annual)3.8B

Net income (annual)392.5M

Social

What share of all stock conversation is about ATR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% +0	0% 0

Feb 7

APTARGROUP INC (ATR) highlighted 157 positive and negative remarks in its 10-K filing, with notable risks including geopolitical tensions, supply chain vulnerabilities, and climate impacts on raw materials.
The company is expected to make waves in the RWA space, with potential for significant growth and development.
APTARGROUP INC (ATR) reported its 2024 Q4 and annual results, with notable risk factors including increased focus on geopolitical risks, supply chain vulnerabilities, and rising institutional ownership concentration.

Generated by AI

Sentiment

Of the messages about ATR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	86.02% -6.87
Bearish	—	—	—	13.98% +6.87

Topics

Of the messages about ATR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	68.33%
Analysts	0%	0%	0%	4.44%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	4.44%
Macro	0%	0%	0%	13.89%
Technical Analysis	0%	0%	0%	8.89%

Community

Of the messages about ATR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	55.86%	34.33%
Newcomers	0%	0%	44.14%	65.67%

Regulars· Aug 10

The price target for AptarGroup, Inc. ($ATR) has been raised by several brokerages, with Bank of America boosting its target to $132.00 and Morgan Stanley raising its target to $122.00.
Insider Hedi Tlili has sold a significant number of shares of $ATR, including 2,500 shares on August 7, 2020, and 35,000 shares in a single transaction.
The majority of brokerages have an "average recommendation" or "rating" of "Buy" for AptarGroup, Inc. ($ATR), with some also upgrading their rating to "Buy" in recent news.

Newcomers· Feb 7

Newcomers to ATR are drawn to its potential for making waves and seeing significant growth in the coming year.
Investors with a focus on high Relative Weakness Alert (RWA) stocks are watching ATR due to its 2-5% price movement, indicating potential breakouts.
ATR is gaining attention in the RWA space, with exciting developments noted by newcomers who are enthusiastic about its prospects.

Generated by AI

News

Aptar partners with MGH on nose-to-brain drug delivery research

15d agoInvesting.com

Aptar Pharma and Massachusetts General Hospital Collaborate on Platform to Establish Predictive, Data-Driven Model for Advancing Nose-to-Brain Drug Delivery

CRYSTAL LAKE, Ill., September 14, 2026--Aptar and Massachusetts General Hospital Collaborate on Platform to Establish Predictive, Data-Driven Model for Advancing Nose-to-Brain Drug Delivery

15d agoYahoo Finance

Aptar Pharma to support Aceso’s inhaled cystic fibrosis candidate’s advance

Aptar's ACT-101 is designed to intervene a step earlier than current CF modulators.

22d agoYahoo Finance

Aptar Beauty powers L’Occitane’s transition to refillable bottles

The custom pump has a 24/410 screw-on neck finish, with the actuator and collar enlarged to fit the broader bottle shape.

1mo agoYahoo Finance

Aptar (ATR) Q2 2026 Earnings Call Transcript

Detailed price information for Aptargroup (ATR-N) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Aptar (ATR) Q2 2026 Earnings Call Transcript | The Motley Fool

Record $1B revenue as pharma growth offsets margin pressure.

1mo agoThe Motley Fool

Also Discussed

Investors talking about ATR also mention

#	Name	Attention
1	Western Asset Inflation-Linked Income FundWIA	0%new
2	BKN - BlackRock Investment Quality Municipal Trust Inc.	——
3	Rio Tinto plc ADRRIO	0%new
4	iShares MSCI Chile ETFECH	0%new
5	White Mountains Insurance Group Ltd.WTM	0%0
6	Beam Therapeutics IncBEAM	0.02%+0.02
7	Qiagen N.V.QGEN	0%+0
8	Sonoco Products CompanySON	0%0
9	CAE Inc.CAE	0%0
10	KLR - Kaleyra, Inc.	——

AptarGroup Inc

Healthcare
Medical Instruments & Supplies

AptarGroup Inc. is a global packaging and dispensing technology company that designs and manufactures drug delivery systems, consumer product dispensers, sealing solutions, and active packaging. AptarGroup Inc. serves pharmaceutical, consumer health, beauty, personal care, home care, food, and beverage markets with products such as pumps, valves, closures, nasal spray systems, inhalers, and elastomeric components used in injectable and other drug packaging applications. The company also provides active material science and digital health solutions that support product protection, dosing, and delivery performance across healthcare and consumer applications. AptarGroup Inc. operates through focused business segments including Pharma, Beauty, and Closures, positioning it as a key supplier to brands that rely on precise dispensing, protective packaging, and differentiated user experience in highly regulated and consumer-facing markets.

Website

Location

265 Exchange Drive

Crystal Lake, IL, 60014

United States

Social

What share of all stock conversation is about ATR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% +0	0% 0

Feb 7

APTARGROUP INC (ATR) highlighted 157 positive and negative remarks in its 10-K filing, with notable risks including geopolitical tensions, supply chain vulnerabilities, and climate impacts on raw materials.
The company is expected to make waves in the RWA space, with potential for significant growth and development.
APTARGROUP INC (ATR) reported its 2024 Q4 and annual results, with notable risk factors including increased focus on geopolitical risks, supply chain vulnerabilities, and rising institutional ownership concentration.

Generated by AI

Sentiment

Of the messages about ATR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	86.02% -6.87
Bearish	—	—	—	13.98% +6.87

Topics

Of the messages about ATR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	68.33%
Analysts	0%	0%	0%	4.44%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	4.44%
Macro	0%	0%	0%	13.89%
Technical Analysis	0%	0%	0%	8.89%

Community

Of the messages about ATR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	55.86%	34.33%
Newcomers	0%	0%	44.14%	65.67%

Regulars· Aug 10

The price target for AptarGroup, Inc. ($ATR) has been raised by several brokerages, with Bank of America boosting its target to $132.00 and Morgan Stanley raising its target to $122.00.
Insider Hedi Tlili has sold a significant number of shares of $ATR, including 2,500 shares on August 7, 2020, and 35,000 shares in a single transaction.
The majority of brokerages have an "average recommendation" or "rating" of "Buy" for AptarGroup, Inc. ($ATR), with some also upgrading their rating to "Buy" in recent news.

Newcomers· Feb 7

Newcomers to ATR are drawn to its potential for making waves and seeing significant growth in the coming year.
Investors with a focus on high Relative Weakness Alert (RWA) stocks are watching ATR due to its 2-5% price movement, indicating potential breakouts.
ATR is gaining attention in the RWA space, with exciting developments noted by newcomers who are enthusiastic about its prospects.

Generated by AI

AptarGroup

Social

Feb 7

Regulars· Aug 10

Newcomers· Feb 7

Aptar partners with MGH on nose-to-brain drug delivery research

Aptar Pharma and Massachusetts General Hospital Collaborate on Platform to Establish Predictive, Data-Driven Model for Advancing Nose-to-Brain Drug Delivery

Aptar Pharma to support Aceso’s inhaled cystic fibrosis candidate’s advance

Aptar Beauty powers L’Occitane’s transition to refillable bottles

Aptar (ATR) Q2 2026 Earnings Call Transcript

Aptar (ATR) Q2 2026 Earnings Call Transcript | The Motley Fool

Also Discussed

AptarGroup Inc

Company Information

Location

Aptar partners with MGH on nose-to-brain drug delivery research

Aptar Pharma and Massachusetts General Hospital Collaborate on Platform to Establish Predictive, Data-Driven Model for Advancing Nose-to-Brain Drug Delivery

Aptar Pharma to support Aceso’s inhaled cystic fibrosis candidate’s advance

Aptar Beauty powers L’Occitane’s transition to refillable bottles

Aptar (ATR) Q2 2026 Earnings Call Transcript

Aptar (ATR) Q2 2026 Earnings Call Transcript | The Motley Fool

Also Discussed

Social

Feb 7

Regulars· Aug 10

Newcomers· Feb 7